Indomethacin pharmacodynamics are altered by surfactant: A possible challenge to current indomethacin dosing guidelines created before surfactant availability

Pediatric Cardiology

Volumn 31, Issue 4, 2010, Pages 505-510

  McPherson, Christopher ^a   Gal, Peter ^b,c   Ransom, J Laurence ^c   Carlos, Rita Q ^c   Dimaguila, Mary Ann V T ^c   Smith, McCrae ^c   Davonzo, Christie ^c   Wimmer Jr , John E ^c  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b University of North Carolina   (United States)

^c The Women's Hospital of Greensboro   (United States)

Author keywords

Indomethacin; Pharmacodynamics; Pharmacokinetics; Surfactant

Indexed keywords

BERACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; FUROSEMIDE; INDOMETACIN;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; ECHOCARDIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEWBORN; PATENT DUCTUS ARTERIOSUS; PRACTICE GUIDELINE; RESPIRATORY DISTRESS SYNDROME; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; BIOLOGICAL PRODUCTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; DUCTUS ARTERIOSUS, PATENT; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FATTY ALCOHOLS; GUIDELINE ADHERENCE; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; KIDNEY; METABOLIC CLEARANCE RATE; PHOSPHORYLCHOLINE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 77954759543     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-009-9628-6     Document Type: Article

References (33)

1. Alpert BS, Lewins MJ, Rowland DW, Grant MJA, Olley PM, Soldin SJ, Swyer PR, Coceani F, Rowe R (1979) Plasma indomethacin levels in preterm newborn infants with symptomatic patent ductus arteriosus-clinical and echocardiographic assessments of response. J Pediatr 95:578-582.
2. Bose CL, Laughon M (2006) Treatment to prevent patency of the ductus arteriosus: beneficial or harmful? J Pediatr 148:713-714.
3. Brash AR, Hickey DE, Graham TP, Stahlman MT, Oates JA, Cotton RB (1981) Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med 305:67-72.
4. Brown Y, Kandrotas RJ, Douglas JB, Gal P (1988) High performance liquid chromatographic determination of indomethacin serum concentration. J Chromatogr 459:275-279.
5. Chorne N, Leonard C, Piecuch R, Clyman RI (2007) Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 119:1165-1174.
6. Christmann V, Liem KD, Semmekrot BA, van de Bor M (2002) Changes in cerebral, renal, and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Pediatr 91:440-446.
7. Clement WA, El-Hakim H, Phillipos EZ, Cote JJ (2008) Unilateral vocal cord paralysis following patent ductus arteriosus ligation in extremely low-birth-weight infants. Arch Otolaryngol Head Neck Surg 134:28-33.
8. Clyman RI, Chome N (2007) Patent ductus arteriosus: evidence for and against treatment. J Pediatr 150:216-219.
9. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE (1976) Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 295:526-529.
10. Gal P (2009) Optimum use of therapeutic drug monitoring and pharmacokinetics-pharmacodynamics in the NICU. J Pediatr Pharmacol Ther 14:66-74.
11. Gal P (2009) Patent ductus arteriosus: Indomethacin, ibuprofen, surgery, or no treatment at all? J Pediatr Pharmacol Ther 14:4-8.
12. Gal P, Ransom JL, Schall S, Weaver RL, Bird A, Brown Y (1990) Indomethacin for patent ductus arteriosus closure: application of serum concentrations and pharmacodynamics to improve response. J Perinatol 10:20-26.
13. Gal P, Ransom JL, Weaver RL, Schall S, Brown Y (1990) Impact of concurrent furosemide on indomethacin pharmacodynamics re: efficacy for PDA closure and renal toxicity. Pharmacotherapy 10(3):238.
14. Gal P, Ransom JL, Weaver RL, Schall S, Wyble LE, Carlos RQ, Brown Y (1991) Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure. Ther Drug Monit 13:42-45.
15. Gal P, Ransom JL, Shaffer CL, Smith MS, Carlos RQ, Brown Y, Schall S (1996) Reopening of the ductus arteriosus after closure with indomethacin: importance of sustained effective indomethacin serum concentrations. J Pediatr 128:719.
16. Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS (1983) Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 102:895-906.
17. Halliday HL, Hirata T, Brady JP (1979) Indomethacin therapy for large patent ductus arteriosus in the very low birth weight infant: results and complications. Pediatrics 64:154-159. (Pubitemid 9218403)
18. Heymann MA, Rudolph AM, Silverman NH (1976) Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 295:530-533.
19. Holford NH, Sheiner LB (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429-453.
20. Jegatheesan P, Ianus V, Buchh B, Yoon G, Chorne N, Ewig A, Lin E, Moon-Grady A, Tacy T, Milstein J, Schreiber M, Padbury J, Clyman R (2008) Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. J Pediatr 153:183-189.
21. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A (2007) Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. J Pediatr 150:229-234.
22. Lemmers PM, Toet MC, van Bel F (2008) Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics 121:142-147.
23. Malcolm WF, Hornik C, Evans A, Smith PB, Cotton CM (2008) Vocal fold paralysis following surgical ductal closure in extremely low birth weight infants: a case series of feeding and respiratory complications. J Perinatol 28:782-785.
24. McPherson C, Gal P, Smith M, Wilder W, Richter S, Ransom JL, Carlos RQ, Dimaguila MAVT, Wimmer JE (2008) Necrotizing enterocolitis in preterm infants with patent ductus arteriosus: does indomethacin increase the risk? J Neonatal-Perinatal Med 1:209-216.
25. Mellander M, Leheup B, Lindstrom DP et al (1984) Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin. J Pediatr 105:138-143.
26. Merritt TA, DiSessa TG, Feldman BH, Kirkpatrick SE, Gluck L, Friedman WF (1978) Closure of the patent ductus arteriosus with ligation and indomethacin: a consecutive experience. J Pediatr 93:639-646.
27. Rane A, Oelz O, Frolich JC, Seyberth HW, Sweetman BJ, Watson JT, Wilkinson GR, Oates JA (1978) Relationship between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther 23:658-668.
28. Shaffer CL, Gal P, Ransom JL, Carlos RQ, Smith MS, Davey AM, Dimaguila MA, Brown YL, Schall SA (2002) Effects of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med 30:343-348.
29. Sun K, Brockman D, Campos B, Pitzer B, Myatt L (2006) Induction of surfactant protein A expression by cortisol facilitates prostaglandin synthesis in human chorionic trophoblasts. J Clin Endocrinol Metab 91:4988-4994.
30. Trus T, Winthrop AL, Pipe S, Shah J, Langer JC, Lau GY (1993) Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. J Pediatr Surg 28:1137-1139.
31. Weiss H, Cooper B, Brook M, Schlueter M, Clyman R (1995) Factors determining reopening of the ductus arteriosus after successful closure with indomethacin. J Pediatr 127:466-471.
32. Yaffe SJ, Friedman WF, Rogers D, Lang P, Ragni M, Saccar C (1980) The disposition of indomethacin in preterm babies. J Pediatr 97:1001-1006.
33. Yeh TF, Wilkes A, Betkerur M, Lilien L, Pildes RS (1982) Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus. J Pediatr 101:433-437.